AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
3.48
+0.06 (1.75%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.36 - 3.49
52 week 2.59 - 5.88
Open 3.44
Vol / Avg. 91,348.00/231,752.00
Mkt cap 159.08M
P/E     -
Div/yield     -
EPS -0.57
Shares 45.31M
Beta 2.02
Inst. own 67%
Aug 1, 2016
Q2 2016 AcelRx Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 22, 2016
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 3:00PM EDT - Add to calendar
Jun 21, 2016
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting - 3:00PM EDT - Add to calendar
May 12, 2016
AcelRx Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 11, 2016
AcelRx Pharmaceuticals Inc at Biocentury BioEquity Europe
May 2, 2016
Q1 2016 AcelRx Pharmaceuticals Inc Earnings Call - Webcast
May 2, 2016
Q1 2016 AcelRx Pharmaceuticals Inc Earnings Release
Apr 5, 2016
AcelRx Pharmaceuticals Inc at EBD BIO-Europe Spring Conference
Mar 29, 2016
AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016 Corporate Call - Webcast
Mar 15, 2016
AcelRx Pharmaceuticals Inc at ROTH Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -363.01% -126.66%
Operating margin -281.72% -103.59%
EBITD margin - -89.36%
Return on average assets -35.38% -22.78%
Return on average equity -155.76% -61.17%
Employees 36 -
CDP Score - -

Address

351 Galveston Dr
REDWOOD CITY, CA 94063-4736
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Richard A. King President
Age: 49
Bio & Compensation  - Reuters
Howard B. Rosen Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 52
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wright-Mitchell Chief Legal Officer
Age: 46
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 61
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 57
Bio & Compensation  - Reuters